ERBB2 and breast cancer: Additionally, the use of neoadjuvant chemotherapy (NAC) has expanded in recent decades, especially with respect to triple-negative (TN) and HER2-positive BC, which exhibit aggressive clinical-pathological features and poor prognosis.